New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Specific components of the tumor immune microenvironment may affect responses to BCMA CAR T-cell therapy

Specific components of the tumor immune microenvironment may affect responses to BCMA CAR T-cell therapy

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainPatients with myeloma whose tumor immune microenvironments had a more diverse baseline T-cell repertoire, fewer marker
Oncology January 22,2024
Specific components of the tumor immune microenvironment may affect responses to BCMA CAR T-cell therapy

Specific components of the tumor immune microenvironment may affect responses to BCMA CAR T-cell therapy

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainPatients with myeloma whose tumor immune microenvironments had a more diverse baseline T-cell repertoire, fewer marker
Oncology January 22,2024
Experts boost activity of potential therapeutic target in triple-negative breast cancer

Experts boost activity of potential therapeutic target in triple-negative breast cancer

by Diana Yates,University of Illinois at Urbana-ChampaignCredit: Unsplash/CC0 Public DomainLess than 20% of diagnosed breast cancers are designated "triple-negative," lacking three typ
Oncology January 22,2024
Experts boost activity of potential therapeutic target in triple-negative breast cancer

Experts boost activity of potential therapeutic target in triple-negative breast cancer

by Diana Yates,University of Illinois at Urbana-ChampaignCredit: Unsplash/CC0 Public DomainLess than 20% of diagnosed breast cancers are designated "triple-negative," lacking three typ
Oncology January 22,2024
Taxane-induced peripheral neuropathy in breast cancer: Frequent, clinically significant, and worse with paclitaxel

Taxane-induced peripheral neuropathy in breast cancer: Frequent, clinically significant, and worse with paclitaxel

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainChemotherapy-induced peripheral neuropathy (CIPN)—nerve pain, tingling, or numbness in the hands or feet—is a common side effect of cer
Oncology January 22,2024
Taxane-induced peripheral neuropathy in breast cancer: Frequent, clinically significant, and worse with paclitaxel

Taxane-induced peripheral neuropathy in breast cancer: Frequent, clinically significant, and worse with paclitaxel

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainChemotherapy-induced peripheral neuropathy (CIPN)—nerve pain, tingling, or numbness in the hands or feet—is a common side effect of cer
Oncology January 22,2024
Race could affect outcomes in head and neck cancers

Race could affect outcomes in head and neck cancers

by Cara Murez HealthDay ReporterBlack patients with head and neck cancers have twice the death rates of white patients, and a new study suggests race itself underlies those differences."What is u
Oncology January 22,2024
Race could affect outcomes in head and neck cancers

Race could affect outcomes in head and neck cancers

by Cara Murez HealthDay ReporterBlack patients with head and neck cancers have twice the death rates of white patients, and a new study suggests race itself underlies those differences."What is u
Oncology January 22,2024
Technique for tracking resistant cancer cells could lead to new treatments for relapsing breast cancer patients

Technique for tracking resistant cancer cells could lead to new treatments for relapsing breast cancer patients

byUniversity of CambridgeCredit: Pixabay/CC0 Public DomainCambridge scientists have managed to identify and kill those breast cancer cells that evade standard treatments in a study in mice. The
Oncology January 22,2024
Technique for tracking resistant cancer cells could lead to new treatments for relapsing breast cancer patients

Technique for tracking resistant cancer cells could lead to new treatments for relapsing breast cancer patients

byUniversity of CambridgeCredit: Pixabay/CC0 Public DomainCambridge scientists have managed to identify and kill those breast cancer cells that evade standard treatments in a study in mice. The
Oncology January 22,2024
Stopping a rare childhood cancer in its tracks

Stopping a rare childhood cancer in its tracks

byCold Spring Harbor LaboratoryScientists discovered targeting a protein called ETV6 can turn Ewing sarcoma cancer cells back to normal-looking and -behaving connective tissue cells, as seen abo
Oncology January 22,2024
Stopping a rare childhood cancer in its tracks

Stopping a rare childhood cancer in its tracks

byCold Spring Harbor LaboratoryScientists discovered targeting a protein called ETV6 can turn Ewing sarcoma cancer cells back to normal-looking and -behaving connective tissue cells, as seen abo
Oncology January 22,2024
Final overall study analysis continues to show benefit of sacituzumab govitecan in advanced HR+ breast cancer

Final overall study analysis continues to show benefit of sacituzumab govitecan in advanced HR+ breast cancer

byDana-Farber Cancer InstituteOverall survival in the intention-to-treat population. This is the planned final analysis of overall survival in the intent-to-treat population of all randomly assi
Oncology January 22,2024
Final overall study analysis continues to show benefit of sacituzumab govitecan in advanced HR+ breast cancer

Final overall study analysis continues to show benefit of sacituzumab govitecan in advanced HR+ breast cancer

byDana-Farber Cancer InstituteOverall survival in the intention-to-treat population. This is the planned final analysis of overall survival in the intent-to-treat population of all randomly assi
Oncology January 22,2024
Peripheral surrogates of tumor burden to guide therapeutic strategies for HPV-associated malignancies

Peripheral surrogates of tumor burden to guide therapeutic strategies for HPV-associated malignancies

by Impact Journals LLCTumor intrinsic and extrinsic factors in the periphery that can serve as proxies of tumor burden. Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.28487A new review
Oncology January 22,2024
Peripheral surrogates of tumor burden to guide therapeutic strategies for HPV-associated malignancies

Peripheral surrogates of tumor burden to guide therapeutic strategies for HPV-associated malignancies

by Impact Journals LLCTumor intrinsic and extrinsic factors in the periphery that can serve as proxies of tumor burden. Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.28487A new review
Oncology January 22,2024
Reconsidering oxygen's role in growth of tumors

Reconsidering oxygen's role in growth of tumors

byYale UniversityGraphical abstract. Credit:Cell Systems(2022). DOI: 10.1016/j.cels.2022.11.003Yale researchers have made a discovery that changes conventional thinking about the rol
Oncology January 22,2024
Reconsidering oxygen's role in growth of tumors

Reconsidering oxygen's role in growth of tumors

byYale UniversityGraphical abstract. Credit:Cell Systems(2022). DOI: 10.1016/j.cels.2022.11.003Yale researchers have made a discovery that changes conventional thinking about the rol
Oncology January 22,2024
Specifically designed diets demonstrate a 'powerful ability' to prevent tumorigenesis, delay tumor growth

Specifically designed diets demonstrate a 'powerful ability' to prevent tumorigenesis, delay tumor growth

byThe Spanish National Cancer Research CentrePrecision nutrition in cancer therapyPrecision nutrition takes into account genetic, physiological and lifestyle factors to develop personalized diet
Oncology January 22,2024
Specifically designed diets demonstrate a 'powerful ability' to prevent tumorigenesis, delay tumor growth

Specifically designed diets demonstrate a 'powerful ability' to prevent tumorigenesis, delay tumor growth

byThe Spanish National Cancer Research CentrePrecision nutrition in cancer therapyPrecision nutrition takes into account genetic, physiological and lifestyle factors to develop personalized diet
Oncology January 22,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com